E
Description
Clinical pharmaceutical company (NASDAQ: ENTA) specialized in small molecule antivirals for virology and immunology. RSV candidates: Zelicapavir (positive Phase 2b) and EDP-323. Discovered glecaprevir (HCV protease inhibitor) included in AbbVie's MAVYRET®. Oncology pipeline with $241.9M runway to 2029.